Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
暂无分享,去创建一个
[1] V. Uversky,et al. Evidence for a Partially Folded Intermediate in α-Synuclein Fibril Formation* , 2001, The Journal of Biological Chemistry.
[2] Min Zhu,et al. Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.
[3] Andrew B West,et al. Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.
[4] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.
[5] V. Uversky,et al. Methionine oxidation, a-synuclein and Parkinson's disease , 2005 .
[6] V. Uversky,et al. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. , 2002, Biochemistry.
[7] D. Selkoe,et al. Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[8] V. Uversky,et al. Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .
[9] S. Hammond,et al. Phospholipase D Stimulates Release of Nascent Secretory Vesicles from the trans-Golgi Network , 1997, The Journal of cell biology.
[10] Andrzej Galat,et al. Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity--targets--functions. , 2003, Current topics in medicinal chemistry.
[11] M. Farrer,et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.
[12] V. Uversky. Intrinsically Disordered Proteins , 2000 .
[13] Ewan W Blanch,et al. A Raman optical activity study of rheomorphism in caseins, synucleins and tau. New insight into the structure and behaviour of natively unfolded proteins. , 2002, European journal of biochemistry.
[14] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[15] M. Beal,et al. Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.
[16] V. Uversky,et al. Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. , 2003, Biochemistry.
[17] M. Goedert,et al. The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy , 2000 .
[18] C. Hertzman,et al. A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.
[19] V. Uversky,et al. Role of individual methionines in the fibrillation of methionine-oxidized α-synuclein , 2004 .
[20] W. Honer,et al. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. , 1998, The American journal of pathology.
[21] L. Iakoucheva,et al. Intrinsic Disorder and Protein Function , 2002 .
[22] L. Mucke,et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.
[23] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[24] H. Dyson,et al. Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.
[25] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] P. Lansbury,et al. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.
[27] V. Uversky,et al. Trimethylamine-N-oxide-induced folding of alpha-synuclein. , 2001, FEBS letters.
[28] W. Spooren,et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. , 2002, EMBO reports.
[29] Ikuko Fujiwara,et al. Microscopic analysis of polymerization dynamics with individual actin filaments , 2002, Nature Cell Biology.
[30] V. Uversky,et al. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. , 2001, Biochemistry.
[31] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[32] V. Uversky,et al. Trimethylamine‐N‐oxide‐induced folding of α‐synuclein , 2001 .
[33] O. Axelson,et al. Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.
[34] M. Vila,et al. Genetic clues to the pathogenesis of Parkinson's disease , 2004, Nature Medicine.
[35] S. Paik,et al. Metal-Catalyzed Oxidation of α-Synuclein in the Presence of Copper(II) and Hydrogen Peroxide , 2000 .
[36] C. Tanner,et al. Environmental factors and Parkinson's disease , 1989, Neurology.
[37] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[38] John Q. Trojanowski,et al. Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.
[39] Theodore W Randolph,et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. , 2003, Biochemistry.
[40] T. Nagatsu. [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.
[41] M. Goedert. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[42] Langston Jw,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .
[43] B. Giasson,et al. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.
[44] R. Crowther,et al. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. , 2000, Neuroscience letters.
[45] Y. Lyubchenko,et al. Effects of nitration on the structure and aggregation of α-synuclein , 2005 .
[46] H. Dyson,et al. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. , 1999, Journal of molecular biology.
[47] A. Minton. Implications of macromolecular crowding for protein assembly. , 2000, Current opinion in structural biology.
[48] K. Jellinger,et al. Neuropathological spectrum of synucleinopathies , 2003, Movement disorders : official journal of the Movement Disorder Society.
[49] M. Citron,et al. Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.
[50] Y. Lyubchenko,et al. Effects of nitration on the structure and aggregation of alpha-synuclein. , 2005, Brain research. Molecular brain research.
[51] D. Ferrington,et al. Repair of oxidized calmodulin by methionine sulfoxide reductase restores ability to activate the plasma membrane Ca-ATPase. , 1999, Biochemistry.
[52] P. Jensen,et al. Pathogenic effects of alpha-synuclein aggregation. , 2005, Brain research. Molecular brain research.
[53] Marc S. Cortese,et al. Flexible nets , 2005, The FEBS journal.
[54] Kurt Jellinger,et al. Amygdala pathology in Parkinson's disease , 2004, Acta Neuropathologica.
[55] Ad Bax,et al. Structure and Dynamics of Micelle-bound Human α-Synuclein* , 2005, Journal of Biological Chemistry.
[56] M. Bennett. The role of α-synuclein in neurodegenerative diseases , 2005 .
[57] K. Prasad,et al. Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells , 2000, Brain Research.
[58] J Q Trojanowski,et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.
[59] Christopher J. Oldfield,et al. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling , 2005, Journal of molecular recognition : JMR.
[60] G. Pielak,et al. Macromolecular crowding in the Escherichia coli periplasm maintains alpha-synuclein disorder. , 2006, Journal of molecular biology.
[61] M. Bennett. The role of alpha-synuclein in neurodegenerative diseases. , 2005, Pharmacology & therapeutics.
[62] L. Lipkin,et al. DIFFUSE INTRACYTOPLASMIC GANGLIONIC INCLUSIONS (LEWY TYPE) ASSOCIATED WITH PROGRESSIVE DEMENTIA AND QUADRIPARESIS IN FLEXION , 1961, Journal of neuropathology and experimental neurology.
[63] J. Trojanowski,et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.
[64] S. Zimmerman,et al. Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. , 1991, Journal of molecular biology.
[65] P. Lansbury,et al. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. , 2000, Biochemistry.
[66] R. Anthony Crowther,et al. Synthetic filaments assembled from C‐terminally truncated α‐synuclein , 1998 .
[67] M. Cookson. Hero versus antihero: The multiple roles of α-synuclein in neurodegeneration , 2006, Experimental Neurology.
[68] M. Spillantini,et al. Alpha‐synuclein dysfunction in Lewy body diseases , 2005, Movement disorders : official journal of the Movement Disorder Society.
[69] D. Marsh,et al. Alpha-synuclein association with phosphatidylglycerol probed by lipid spin labels. , 2003, Biochemistry.
[70] N. Wood,et al. Molecular pathogenesis of Parkinson's disease. , 2005, Human molecular genetics.
[71] A Keith Dunker,et al. Natively Disordered Proteins , 2004, Applied bioinformatics.
[72] Kiowa S. Bower,et al. Accelerated α‐synuclein fibrillation in crowded milieu , 2002 .
[73] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[74] V. Uversky,et al. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. , 2004, Biochemistry.
[75] A. Singleton,et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. , 2004, Brain : a journal of neurology.
[76] M. Goedert,et al. Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.
[77] Thomas C. Südhof,et al. α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration , 2005, Cell.
[78] Paul H. Axelsen,et al. The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.
[79] Vladimir N Uversky,et al. What does it mean to be natively unfolded? , 2002, European journal of biochemistry.
[80] S. Tsuji,et al. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. , 1998, Neuroscience letters.
[81] P. Blumbergs,et al. Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.
[82] Matthew J. Farrer,et al. Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .
[83] W. Gong,et al. The flavonoid baicalin exhibits anti-inflammatory activity by binding to chemokines. , 2000, Immunopharmacology.
[84] J. Trojanowski,et al. Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.
[85] J. Trojanowski,et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[86] Leonard Petrucelli,et al. Molecular pathogenesis of Parkinson disease. , 2005, Archives of neurology.
[87] Jeff Kuret,et al. Rapid Anionic Micelle-mediated α-Synuclein Fibrillization in Vitro* , 2003, Journal of Biological Chemistry.
[88] N. Voelcker,et al. Annular α‐synuclein species from purified multiple system atrophy inclusions , 2004 .
[89] S. Bottomley,et al. Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[90] T. Iwatsubo,et al. Phosphorylation of α-synuclein characteristic of synucleinopathy lesions is recapitulated in α-synuclein transgenic Drosophila , 2003, Neuroscience Letters.
[91] R. Edwards,et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[92] H. Vorum,et al. Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.
[93] E. Love,et al. Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.
[94] P J McLean,et al. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.
[95] P. Romero,et al. Sequence complexity of disordered protein , 2001, Proteins.
[96] H. Braak,et al. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by α-synuclein immunocytochemistry , 1999, Neuroscience Letters.
[97] Nigel J. Cairns,et al. Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.
[98] V. Uversky,et al. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. , 2004, Chemistry & biology.
[99] Jeff Kuret,et al. Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. , 2003, The Journal of biological chemistry.
[100] R. Perrin,et al. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.
[101] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.
[102] E. Stadtman,et al. Methionine residues as endogenous antioxidants in proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[103] S. Scarlata,et al. Membrane binding and self-association of alpha-synucleins. , 2001, Biochemistry.
[104] F. Kamp,et al. Binding of α-Synuclein Affects the Lipid Packing in Bilayers of Small Vesicles* , 2006, Journal of Biological Chemistry.
[105] Christopher J. Oldfield,et al. Intrinsically disordered protein. , 2001, Journal of molecular graphics & modelling.
[106] P. Romero,et al. Natively Disordered Proteins , 2008, Applied bioinformatics.
[107] N. Voelcker,et al. Annular alpha-synuclein species from purified multiple system atrophy inclusions. , 2004, Journal of neurochemistry.
[108] P. Lansbury,et al. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. , 2000, Annals of the New York Academy of Sciences.
[109] P. Lansbury,et al. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. , 2002, Biochemistry.
[110] R. Ellis. Macromolecular crowding : obvious but underappreciated , 2022 .
[111] V. Uversky,et al. Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.
[112] R. Nussbaum,et al. Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.
[113] G. Johnson,et al. Transglutaminase Cross‐Linking of the τ Protein , 1995 .
[114] Mark R Cookson,et al. The biochemistry of Parkinson's disease. , 2005, Annual review of biochemistry.
[115] W. Woods,et al. A Novel Mechanism of Interaction between α-Synuclein and Biological Membranes , 2006 .
[116] D. Selkoe,et al. Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. , 2003, The Journal of biological chemistry.
[117] M. L. Schmidt,et al. Pathobiology of the Lewy body. , 1999, Advances in neurology.
[118] N. Wood,et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.
[119] N. Bonini,et al. Snaring the Function of α-Synuclein , 2005, Cell.
[120] J Q Trojanowski,et al. Synucleinopathies: clinical and pathological implications. , 2001, Archives of neurology.
[121] C. C. Johnson,et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. , 1999, Neurotoxicology.
[122] V. Uversky,et al. Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils , 2004 .
[123] Vladimir N Uversky,et al. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. , 2002, Neurotoxicology.
[124] A. Goldberg,et al. PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.
[125] E. Masliah,et al. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. , 1995, Biochemistry.
[126] Vladimir N Uversky,et al. A Protein-Chameleon: Conformational Plasticity of α-Synuclein, a Disordered Protein Involved in Neurodegenerative Disorders , 2003, Journal of biomolecular structure & dynamics.
[127] V. Uversky,et al. The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.
[128] A. Fink. Natively unfolded proteins. , 2005, Current opinion in structural biology.
[129] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[130] Michel Goedert,et al. Alpha-synuclein and neurodegenerative diseases , 2001, Nature Reviews Neuroscience.
[131] T. Iwatsubo,et al. Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain , 2003 .
[132] P Falkai,et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. , 1999, Neuroscience letters.
[133] D. Heber,et al. Baicalin is a major component of PC‐SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest , 2001, The Prostate.
[134] D. A. Monte. The role of environmental agents in Parkinson's disease , 2001, Clinical Neuroscience Research.
[135] Christopher G. Adda,et al. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. , 2004, Journal of molecular biology.
[136] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[137] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.
[138] V. Uversky,et al. Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.
[139] G. Irvine,et al. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. , 2000, European journal of biochemistry.
[140] H. Kato,et al. Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. , 2006, Biochemistry.
[141] Gary J. Pielak,et al. Macromolecular Crowding in the Escherichia coli Periplasm Maintains α-Synuclein Disorder , 2006 .
[142] Soo-Youl Kim,et al. Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[143] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[144] A. Manning-Boğ,et al. Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.
[145] H. Federoff,et al. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? , 2005, Brain research. Molecular brain research.
[146] V. Uversky,et al. Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. , 2003, Protein science : a publication of the Protein Society.
[147] Charles N. Serhan,et al. Altered Fatty Acid Composition of Dopaminergic Neurons Expressing α-Synuclein and Human Brains with α-Synucleinopathies* , 2003, Journal of Biological Chemistry.
[148] Pico Caroni,et al. Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.
[149] E. Masliah,et al. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.
[150] V. Uversky,et al. Nitration inhibits fibrillation of human α‐synuclein in vitro by formation of soluble oligomers , 2003 .
[151] P. Auluck,et al. Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.
[152] D. Dickson,et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease , 1991, Neurology.
[153] S E Ide,et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.
[154] Shigeo Hirai,et al. NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy , 1998, Acta Neuropathologica.
[155] Robert Edwards,et al. Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.
[156] V. Uversky,et al. Certain Metals Trigger Fibrillation of Methionine-oxidized α-Synuclein* , 2003, Journal of Biological Chemistry.
[157] R. Casadio,et al. Effect of molecular confinement on internal enzyme dynamics: frequency domain fluorometry and molecular dynamics simulation studies. , 2002, Biopolymers.
[158] K. Wakabayashi,et al. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy , 2004, Neuropathology and applied neurobiology.
[159] G J Pielak,et al. Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. , 2001, Protein science : a publication of the Protein Society.
[160] A. Young,et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[161] Zoran Obradovic,et al. The protein trinity—linking function and disorder , 2001, Nature Biotechnology.
[162] P. Tompa. The interplay between structure and function in intrinsically unstructured proteins , 2005, FEBS letters.
[163] K. Herholz,et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure , 1999, Journal of Neurology.
[164] Y. Agid,et al. Clinical and pathological features in hydrocarbon‐induced Parkinsonism , 1996, Annals of neurology.
[165] H. Ischiropoulos,et al. Biological selectivity and functional aspects of protein tyrosine nitration. , 2003, Biochemical and biophysical research communications.
[166] D. D. Di Monte. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet. Neurology.
[167] David W. Miller,et al. α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication , 2004, Neurology.
[168] S. Lindquist,et al. α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.
[169] G. Irvine,et al. Identification of the region of non‐Aβ component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity , 2001, Journal of neurochemistry.
[170] Vladimir N. Uversky,et al. Forcing Nonamyloidogenic β-Synuclein To Fibrillate† , 2005 .
[171] G. Irvine,et al. The N‐terminal region of non‐Aβ component of Alzheimer's Disease amyloid is responsible for its tendency to assume β‐sheet and aggregate to form fibrils , 1998 .
[172] E. Masliah,et al. C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders , 2000, Acta Neuropathologica.
[173] P. Højrup,et al. &agr;-Synuclein filaments bind the transcriptional regulator HMGB-1 , 2004, Neuroreport.
[174] Donato A Di Monte,et al. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? , 2003, The Lancet Neurology.
[175] R. Ferrante,et al. Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.
[176] S. Lindquist,et al. Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.
[177] Smita Patel,et al. Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.
[178] E. Altschuler,et al. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. , 1999, Medical hypotheses.
[179] Christopher G. Adda,et al. Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity , 2004 .
[180] P. Fraser,et al. α‐Synuclein–synaptosomal membrane interactions , 2004 .
[181] Hideo Fujiwara,et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.
[182] Takeshi Iwatsubo,et al. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.
[183] Peter Tompa,et al. The role of structural disorder in the function of RNA and protein chaperones , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[184] A. Jonas,et al. Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.
[185] J. Trojanowski,et al. Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.
[186] A. Singleton,et al. Association between cardiac denervation and parkinsonism caused by α‐synuclein gene triplication , 2004 .
[187] N. Copeland,et al. Chromosomal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[188] B. Festoff,et al. Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. , 1994, FEBS letters.
[189] P. S. St George-Hyslop,et al. α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.
[190] Sebastian Doniach,et al. Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.
[191] F. Kamp,et al. Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. , 2006, The Journal of biological chemistry.
[192] R. Perrin,et al. Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.
[193] B. Festoff,et al. Cross‐linking of β‐amyloid protein precursor catalysed by tissue transglutaminase , 1994 .
[194] J. Langston,et al. Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.
[195] Z. Obradovic,et al. Identification and functions of usefully disordered proteins. , 2002, Advances in protein chemistry.
[196] W. Dauer,et al. Parkinson's Disease Mechanisms and Models , 2003, Neuron.
[197] L. Meijer,et al. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.
[198] V. Uversky,et al. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. , 2005, Glycobiology.
[199] J. Trojanowski,et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.
[200] W. Vogt. Oxidation of methionyl residues in proteins: tools, targets, and reversal. , 1995, Free radical biology & medicine.
[201] I. McKeith,et al. Pathophysiology of synuclein aggregation in Lewy body disease , 2006, Mechanisms of Ageing and Development.
[202] S. Furesz. Chemical and biological properties of rifampicin. , 1970, Antibiotica et chemotherapia. Fortschritte. Advances. Progres.
[203] M. Farrer,et al. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.
[204] V. Uversky,et al. Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations* , 2001, The Journal of Biological Chemistry.
[205] M. Raftery,et al. αB-Crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy , 2009, Neurotoxicity Research.
[206] D. Housman,et al. New Directions for Neurodegenerative Disease Therapy: Using Chemical Compounds to Boost the Formation of Mutant Protein Inclusions , 2006, Cell cycle.
[207] Leonidas Stefanis,et al. α-Synuclein Overexpression in PC12 and Chromaffin Cells Impairs Catecholamine Release by Interfering with a Late Step in Exocytosis , 2006, The Journal of Neuroscience.
[208] L. Golbe. Alpha-synuclein and Parkinson's disease. , 2003, Advances in neurology.
[209] Susan Lindquist,et al. Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or α-Synuclein , 2003, Science.
[210] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[211] Ji An Wu,et al. Anti-HIV activity of medicinal herbs: usage and potential development. , 2001, The American journal of Chinese medicine.
[212] P. Blumbergs,et al. Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.
[213] E. Masliah,et al. α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.
[214] Hideo Fujiwara,et al. Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .
[215] A Keith Dunker,et al. Intrinsic disorder and protein function. , 2002, Biochemistry.
[216] P. Radivojac,et al. PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .
[217] Jie Li,et al. The Association of α-Synuclein with Membranes Affects Bilayer Structure, Stability, and Fibril Formation* , 2003, Journal of Biological Chemistry.
[218] Peter L. Lantos,et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.
[219] J Kim,et al. Copper(II)-induced self-oligomerization of alpha-synuclein. , 1999, The Biochemical journal.
[220] J. Trojanowski,et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. , 2000, The American journal of pathology.
[221] F. Forastiere,et al. Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users , 2002, Neurological Sciences.
[222] M Yasui,et al. Calcium, magnesium and aluminum concentrations in Parkinson's disease. , 1992, Neurotoxicology.
[223] C. Goetz,et al. A pure parkinsonian syndrome following acute carbon monoxide intoxication. , 1982, Archives of neurology.
[224] M. Frasier,et al. Magnesium Inhibits Spontaneous and Iron-induced Aggregation of α-Synuclein* , 2002, The Journal of Biological Chemistry.
[225] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[226] R. Kisilevsky. Review: amyloidogenesis-unquestioned answers and unanswered questions. , 2000, Journal of structural biology.
[227] L. Meijer,et al. Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.
[228] V. Uversky,et al. Role of Protein−Water Interactions and Electrostatics in α-Synuclein Fibril Formation† , 2004 .
[229] Robert L Nussbaum,et al. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. , 2005, Biochemistry.
[230] P. Tompa,et al. Structural disorder throws new light on moonlighting. , 2005, Trends in biochemical sciences.
[231] Peter T. Lansbury,et al. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.
[232] A. Lang,et al. Interface between tauopathies and synucleinopathies: A tale of two proteins , 2006, Annals of neurology.
[233] A. Fulton,et al. How crowded is the cytoplasm? , 1982, Cell.
[234] H. Ischiropoulos. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. , 1998, Archives of biochemistry and biophysics.
[235] G. Johnson,et al. Transglutaminase cross-linking of the tau protein. , 1995, Journal of neurochemistry.
[236] A. Morris,et al. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.
[237] K. Beyer. α-Synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers , 2006, Acta Neuropathologica.
[238] J. Adair,et al. Parkinsonism from methanol poisoning: Benefit from treatment with anti‐parkinson drugs , 1999, Movement disorders : official journal of the Movement Disorder Society.
[239] C. Hogstedt,et al. Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury--a case-referent study. , 1981, Scandinavian journal of work, environment & health.
[240] E. Masliah,et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.
[241] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[242] M. Brin,et al. Immunohistochemical localization and distribution of torsinA in normal human and rat brain , 2000, Brain Research.
[243] Min Zhu,et al. Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.
[244] Zsuzsanna Dosztányi,et al. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content , 2005, Bioinform..
[245] Jie Li,et al. Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[246] A. Brice,et al. Alpha-synuclein and Parkinson's disease , 2000, Cellular and Molecular Life Sciences CMLS.
[247] Hideo Fujiwara,et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. , 2003, Journal of neuropathology and experimental neurology.
[248] J. Trojanowski,et al. Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.
[249] P. Lansbury,et al. Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .
[250] T. Iwatsubo,et al. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. , 2003, Neuroscience Letters.
[251] V. Uversky,et al. Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. , 2003, The Journal of biological chemistry.
[252] V. Buchman,et al. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. , 2003, Neuropharmacology.
[253] T. Iwatsubo,et al. Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. , 2004, Acta neuropathologica.
[254] V. Uversky,et al. Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .
[255] T. Südhof,et al. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. , 2005, Cell.
[256] C. C. Johnson,et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.
[257] Clemens R Scherzer,et al. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. , 2003, Human molecular genetics.
[258] Howard J Federoff,et al. Convergent Pathobiologic Model of Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.
[259] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[260] P. Axelsen,et al. Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .
[261] V. Uversky,et al. Methionine oxidation, alpha-synuclein and Parkinson's disease. , 2005, Biochimica et biophysica acta.
[262] R. Nussbaum,et al. Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice. , 2005, Journal of neurochemistry.
[263] J. Benovic,et al. Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.
[264] P. Ballard,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983, The New England journal of medicine.
[265] Hitoshi Takahashi,et al. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease , 1997, Neuroscience Letters.
[266] D. Allan Butterfield,et al. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins , 2001, Mechanisms of Ageing and Development.
[267] M. E. Clark,et al. Living with water stress: evolution of osmolyte systems. , 1982, Science.
[268] M. Brin,et al. TorsinA accumulation in Lewy bodies in sporadic Parkinson’s disease , 2000, Brain Research.
[269] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[270] V. Uversky,et al. Polycation‐induced oligomerization and accelerated fibrillation of human α‐synuclein in vitro , 2003 .
[271] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[272] J. Jeng,et al. Environmental risk factors and Parkinson's disease , 1997, Neurology.
[273] V. Uversky,et al. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. , 2002, FEBS letters.
[274] V. Uversky,et al. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.
[275] J. Ridet,et al. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[276] J. Trojanowski,et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.
[277] M. Farrer,et al. Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .
[278] Seung-Jae Lee,et al. Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.
[279] R. Jakes,et al. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of α‐synuclein protein implicated in Parkinson's disease , 1998, FEBS letters.
[280] A Keith Dunker,et al. Combining prediction, computation and experiment for the characterization of protein disorder. , 2004, Current opinion in structural biology.
[281] V. Uversky,et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.
[282] Vladimir N. Uversky,et al. Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration , 2004, Cell and Tissue Research.
[283] P. S. St George-Hyslop,et al. alpha-Synuclein membrane interactions and lipid specificity. , 2000, The Journal of biological chemistry.
[284] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[285] E. Stadtman,et al. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. , 1993, Annual review of biochemistry.
[286] A. Minton,et al. Effect of a concentrated "inert" macromolecular cosolute on the stability of a globular protein with respect to denaturation by heat and by chaotropes: a statistical-thermodynamic model. , 2000, Biophysical journal.
[287] D. Clayton,et al. Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.
[288] Susan E Daniel,et al. Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain , 2000, Neuroscience Letters.
[289] A. Singleton,et al. alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.
[290] D. Higgins,et al. In Vivo Labeling of Mitochondrial Complex I (NADH:UbiquinoneOxidoreductase) in Rat Brain Using [3H]Dihydrorotenone , 2000, Journal of neurochemistry.
[291] V. Uversky,et al. Agrin binds α-synuclein and modulates α-synuclein fibrillation , 2005 .
[292] Daniel Otzen,et al. p25α Stimulates α-Synuclein Aggregation and Is Co-localized with Aggregated α-Synuclein in α-Synucleinopathies* , 2005, Journal of Biological Chemistry.
[293] Patrick R Hof,et al. Distribution and immunohistochemical characterization of torsinA immunoreactivity in rat brain , 2001, Brain Research.
[294] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[295] P. Caroni,et al. Neuropathology in mice expressing human alpha-synuclein. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[296] Makoto Hashimoto,et al. β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.
[297] Zeger Debyser,et al. The aggregation of alpha‐synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[298] Kiowa S. Bower,et al. Accelerated alpha-synuclein fibrillation in crowded milieu. , 2002, FEBS letters.
[299] T. Iwatsubo,et al. Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy , 2004, Acta Neuropathologica.
[300] P. Fraser,et al. Review: modulating factors in amyloid-beta fibril formation. , 2000, Journal of structural biology.
[301] C. C. Lin,et al. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. , 2000, Anticancer research.
[302] Matthew P Frosch,et al. The Formation of Highly Soluble Oligomers of α-Synuclein Is Regulated by Fatty Acids and Enhanced in Parkinson's Disease , 2003, Neuron.
[303] S. Murayama,et al. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein , 1998, Neurology.
[304] P. Fraser,et al. alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. , 2004, European journal of biochemistry.
[305] R. Uitti,et al. Parkinsonism induced by solvent abuse , 1994, Annals of neurology.
[306] Miguel A Hernán,et al. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.
[307] C. Griesinger,et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.
[308] K. Arima,et al. Tubulin seeds alpha-synuclein fibril formation. , 2002, The Journal of biological chemistry.
[309] M. Frasier,et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. , 2002, The Journal of biological chemistry.
[310] Akihiko Iwai,et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.
[311] P. Tompa. Intrinsically unstructured proteins. , 2002, Trends in biochemical sciences.
[312] Philippe Hantraye,et al. MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.
[313] N. Voelcker,et al. Calcium(II) selectively induces α‐synuclein annular oligomers via interaction with the C‐terminal domain , 2004, Protein science : a publication of the Protein Society.
[314] David F. Clayton,et al. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.
[315] C. W. Olanow,et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.
[316] J. Trojanowski,et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.
[317] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[318] D. Eliezer,et al. Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.
[319] Hui-Bie F. Xu,et al. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. , 2001, Pharmacological research.
[320] Gary J. Pielak,et al. Solvent‐induced collapse of α‐synuclein and acid‐denatured cytochrome c , 2001 .
[321] C. Lavedan. The synuclein family. , 1998, Genome research.
[322] P. Lansbury,et al. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.
[323] P. Fraser,et al. Review: Modulating Factors in Amyloid-β Fibril Formation , 2000 .
[324] Colin L. Masters,et al. α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores , 1999, Neuroscience Letters.
[325] M. Hallett,et al. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II , 2007, Journal of neuropathology and experimental neurology.
[326] K. Arima,et al. Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.
[327] Shubo Han,et al. The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.
[328] D. Eliezer,et al. Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.
[329] R A Crowther,et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.
[330] M. Goedert,et al. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. , 2000, Annals of the New York Academy of Sciences.
[331] Kiowa S. Bower,et al. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. , 2002, Neurotoxicology.
[332] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[333] C. Tanner,et al. Epidemiology of Parkinson's disease and akinetic syndromes , 2000, Current opinion in neurology.
[334] J Kim,et al. Aluminum-induced structural alterations of the precursor of the non-A beta component of Alzheimer's disease amyloid. , 1997, Archives of biochemistry and biophysics.
[335] M. Hallett,et al. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I , 2007, Journal of neuropathology and experimental neurology.
[336] Min Zhu,et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. , 2004, The Journal of biological chemistry.
[337] M. Vila,et al. α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.
[338] J. Valentine,et al. Crowding and hydration effects on protein conformation: a study with sol-gel encapsulated proteins. , 2001, Journal of molecular biology.
[339] L. Forno,et al. Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.
[340] R. Nussbaum,et al. Fatty acid incorporation is decreased in astrocytes cultured from α‐synuclein gene‐ablated mice , 2005 .
[341] S. Lindquist,et al. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. , 2003, Science.
[342] David F. Clayton,et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.
[343] S. Paik,et al. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide. , 2000, Archives of biochemistry and biophysics.
[344] V. Uversky,et al. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. , 2003, FEBS letters.
[345] Zheng Rong Yang,et al. RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins , 2005, Bioinform..
[346] V. Buchman,et al. Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease , 2003, Neuropharmacology.
[347] B. Hyman,et al. Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.
[348] V. Uversky,et al. Nuclear localization of alpha-synuclein and its interaction with histones. , 2003, Biochemistry.
[349] A. Minton,et al. The Influence of Macromolecular Crowding and Macromolecular Confinement on Biochemical Reactions in Physiological Media* , 2001, The Journal of Biological Chemistry.
[350] V. Uversky,et al. Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. , 2006, Biochemistry.
[351] H. Vorum,et al. Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. , 2001, The Journal of biological chemistry.
[352] L. Serpell,et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[353] J. Valentine,et al. Molecular confinement influences protein structure and enhances thermal protein stability , 2001, Protein science : a publication of the Protein Society.
[354] P. Lansbury. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[355] Ralf Langen,et al. Structure of membrane-bound α-synuclein studied by site-directed spin labeling , 2004 .
[356] Nutan Sharma,et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of α‐synuclein aggregation , 2002, Journal of neurochemistry.
[357] Min Zhu,et al. Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. , 2006, Biochemistry.
[358] D. Neill,et al. Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.
[359] H. Morris. Genetics of Parkinson's disease , 2005, Annals of medicine.
[360] Hitoshi Takahashi,et al. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy , 1998, Neuroscience Letters.
[361] Jing Zhang,et al. Identification of Novel Proteins Associated with Both α-Synuclein and DJ-1*S , 2007, Molecular & Cellular Proteomics.
[362] V. Uversky. Natively unfolded proteins: A point where biology waits for physics , 2002, Protein science : a publication of the Protein Society.
[363] J. Culvenor,et al. α‐Synuclein Immunoisolation of Glial Inclusions from Multiple System Atrophy Brain Tissue Reveals Multiprotein Components , 1999, Journal of neurochemistry.
[364] K. Arima,et al. Tubulin Seeds α-Synuclein Fibril Formation* , 2002, The Journal of Biological Chemistry.
[365] J. Gorell,et al. Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.
[366] Obradovic,et al. Predicting Protein Disorder for N-, C-, and Internal Regions. , 1999, Genome informatics. Workshop on Genome Informatics.
[367] A. Doig,et al. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers. , 2006, Biochemistry.
[368] P. Jensen,et al. Pathogenic effects of α-synuclein aggregation , 2005 .
[369] P. Lansbury,et al. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? , 2002, Biochemistry.
[370] C. Tanner,et al. The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.
[371] Ralf Langen,et al. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[372] R. G. Lee,et al. Parkinson's disease , 1993, Neurology.
[373] R A Crowther,et al. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. , 1998, FEBS letters.
[374] A. Seidler,et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease , 1996, Neurology.